Evidence map›Paper›PMID 41155568›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Pre-Emptive Drug Safety Evaluation of Iclepertin (BI-425809) Using Real-World Data and Virtual Addition of This Medication to the Actual Drug Regimen of Individuals from Large Populations.

Sebastian Härtter, Veronique Michaud, Matt K Smith, Pamela Dow, Gerald Condon, Michael Desch, Jacques Turgeon

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sebastian HärtterTranslational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co, KG, Binger Str. 173, 55216 Ingelheim am Rhein, Germany.
Veronique MichaudGalenusRx Inc., 17101 Porter Avenue, P.O. Box 560025, Montverde, FL 34756, USA.
Matt K SmithGalenusRx Inc., 17101 Porter Avenue, P.O. Box 560025, Montverde, FL 34756, USA.
Pamela DowGalenusRx Inc., 17101 Porter Avenue, P.O. Box 560025, Montverde, FL 34756, USA.ORCID 0000-0002-9983-8545
Gerald CondonGalenusRx Inc., 17101 Porter Avenue, P.O. Box 560025, Montverde, FL 34756, USA.
Michael DeschTranslational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co, KG, Binger Str. 173, 55216 Ingelheim am Rhein, Germany.
Jacques TurgeonGalenusRx Inc., 17101 Porter Avenue, P.O. Box 560025, Montverde, FL 34756, USA.ORCID 0000-0002-7978-9280

Funding

Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Cholinergic Drug Induced DementiaR44AG071386 · NIA · HESPEROS, LLC · PI James J Hickman, Jacques Turgeon · 2021 to 2026
$5.0M
NIA NIH HHS R44 AG071386
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BI-425809biosimulationCYP450drug claimsdrug-induced LQTSdrug safetyiclepertinpharmacovigilancereal-world data

Identifiers

PMID41155568
PMCPMC12566928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.